Weight-Loss drug tirzepatide may help keep heart rhythm steady after ablation

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 and 80 years. 2. Diagnosed with persistent atrial fibrillation and scheduled for de novo catheter ablation. 3. Body mass index (BMI) ≥27 kg/m² at screening accompanied by at least one weight-related comorbidity (including cardiovascular disease, hypertension, dyslipidemia, or prediabetes). 4. Able and willing to provide written informed consent. Exclusion Criteria: 1. Long-standing AF or marked left atrial enlargement (persistent AF duration \> 5 years or left atrial anterior-posterior diameter \> 50 mm). 2. AF secondary to reversible causes (e.g., hyperthyroidism, acute infection, acute pulmonary embolism, recent cardiac surgery). 3. Severe structural heart disease that may significantly affect ablation outcomes (e.g., hypertrophic cardiomyopathy, rheumatic valvular disease, dilated cardiomyopathy). 4. Planned major non-AF-related surgery or interventional procedure within 3 months. 5. Other arrhythmias requiring chronic antiarrhythmic drug therapy. 6. Intracardiac thrombus or any contraindication to catheter ablation as judged by the investigator. 7. Active systemic infection at screening. 8. Contraindications to tirzepatide or GLP-1/GIP receptor agonists (e.g., prior serious hypersensitivity, personal or family history of medullary thyroid carcinoma or MEN2, history of clinically significant pancreatitis, severe gastrointestinal disease that may impair tolerance or absorption). 9. Poorly controlled type 1 diabetes, recent diabetic ketoacidosis, end-stage renal disease requiring dialysis, or severe hepatic dysfunction judged clinically significant. 10. Pregnancy, breastfeeding, or women of childbearing potential unwilling or unable to use adequate contraception during the study. 11. Participation in another interventional clinical study within 30 days prior to screening or planned participation during the study period. 12. Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation, including inability to comply with study procedures or follow-up.